Evidence map›Paper›PMID 29207946›Full record

SynthesisBMC geriatrics2017

Achieved systolic blood pressure in older people: a systematic review and meta-analysis.

Aline A I Moraes, Cristina P Baena, Taulant Muka, Arjola Bano, Adriana Buitrago-Lopez, Ana Zazula, Bruna O Erbano, Nicolle A Schio, Murilo H Guedes, Wichor M Bramer and 2 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC geriatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Continuity of Care and the Control of High Blood Pressure at Colombian Primary Care Services.Inquiry : a journal of medical care organization, provision and financing
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Aline A I MoraesPós Graduação de Ciências da Saúde, Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, 1155 - Parque Tecnológico 06, Curitiba, Paraná, CEP: 80.215-901, Brazil. alineiannoni@gmail.com.
Cristina P BaenaPós Graduação de Ciências da Saúde, Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, 1155 - Parque Tecnológico 06, Curitiba, Paraná, CEP: 80.215-901, Brazil.
Taulant MukaDepartment of Epidemiology, Erasmus MC, Erasmus MC, University Medical Center Rotterdam Office Na 29-16, PO Box 2040, 3000, CA, Rotterdam, The Netherlands.
Arjola BanoDepartment of Epidemiology, Erasmus MC, Erasmus MC, University Medical Center Rotterdam Office Na 29-16, PO Box 2040, 3000, CA, Rotterdam, The Netherlands.
Adriana Buitrago-LopezUniversidad Javeriana. Pontificia Universidad Javeriana, Carrera 7 No. 40 - 62, Bogotá D.C., Colombia.
Ana ZazulaEscola de Medicina, Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, 1155 - Parque Tecnológico 06, Curitiba, Paraná, CEP: 80.215-901, Brazil.
Bruna O ErbanoEscola de Medicina, Faculdade Evangélica do Paraná, Rua Padre Anchieta, 2770, Curitiba, Paraná, CEP80730-000, Brazil.
Nicolle A SchioEscola de Medicina, Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, 1155 - Parque Tecnológico 06, Curitiba, Paraná, CEP: 80.215-901, Brazil.
Murilo H GuedesEscola de Medicina, Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, 1155 - Parque Tecnológico 06, Curitiba, Paraná, CEP: 80.215-901, Brazil.
Wichor M BramerMedical Library Erasmus MC, University Medical Center Rotterdam Office Na 29-16, PO Box 2040, 3000, CA, Rotterdam, The Netherlands.
Oscar H FrancoDepartment of Epidemiology, Erasmus MC, Erasmus MC, University Medical Center Rotterdam Office Na 29-16, PO Box 2040, 3000, CA, Rotterdam, The Netherlands.
José Rocha Faria-NetoPós Graduação de Ciências da Saúde, Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, 1155 - Parque Tecnológico 06, Curitiba, Paraná, CEP: 80.215-901, Brazil.
Pontifícia Universidade Católica do Paraná · BRErasmus MC · NLFaculdade Evangélica do Paraná · BRPontificia Universidad Javeriana · CO

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 233188/2014-2
6 · The paper itself

Abstract

backgroundIt remains unclear into which level the systolic blood pressure (SBP) should be lowered in order to provide the best cardiovascular protection among older people. Hypertension guidelines recommendation on attaining SBP levels <150 mmHg in this population is currently based on experts' opinion. To clarify this issue, we systematically reviewed and quantified available evidence on the impact of achieving different SBP levels <150 mmHg on various adverse outcomes in subjects aged ≥60 years old receiving antihypertensive drug treatment.

methodsWe searched 8 databases to identify randomized controlled trials (RCTs) and post-hoc analyses or subanalyses of RCTs reporting the effects of attaining different SBP levels <150 mmHg on the risk of stroke, acute myocardial infarction, heart failure, cardiovascular mortality and all-cause mortality in participants aged ≥60 years. We performed random-effects meta-analyses stratified by study design.

resultsEleven studies (> 33,600 participants) were included. Compared with attaining SBP levels ≥140 mmHg, levels of 130 to <140 mmHg were not associated with lower risk of outcomes in the meta-analysis of RCTs, whereas there was an associated reduction of cardiovascular mortality (RR 0.72, 95% CI 0.59-0.88) and all-cause mortality (RR 0.86, 95% CI 0.75-0.99) in the meta-analysis of post-hoc analyses or subanalyses of RCTs. Limited and conflicting data were available for the SBP levels of <130 mmHg and 140 to <150 mmHg.

conclusionsAmong older people, there is suggestive evidence that achieving SBP levels of 130 to <140 mmHg is associated with lower risks of cardiovascular and all-cause mortality. Future trials are required to confirm these findings and to provide additional evidence regarding the <130 and 140 to <150 mmHg SBP levels.

Indexed as

AgedAntihypertensive AgentsBlood PressureCardiovascular DiseasesHumansHypertensionMiddle AgedRandomized Controlled Trials as TopicRisk Reduction BehaviorAntihypertensive AgentsAgedAntihypertensive agentsAntihypertensive drugsAntihypertensivesBlood pressureHypertensionOlder people

Identifiers

PMID29207946
PMCPMC5717809
OpenAlexW2772144073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.